

Withdrawals

Payers' View on Causes, Impact and Consequences

HMA/EMA multi-stakeholder workshop on shortages Amsterdam March 2, 2023

Dr. Michael Ermisch - GKV-Spitzenverband



General Categories of Withdrawals

Motives and Consequences





Protects

patients from

future harm

e.g. Interferon α, Alemtuzumab, Potassium bromide

Economic Reasons

Strategy for repurposing / reintroduction w/ steep price increases Challenges arising from lack of therapeutic alternatives

Lack of

transparency of

Deprioritisation of smaller patient groups

Company decision

decision rationale